Skinbiotherapeutics Share Discussion Threads

[thanatos abysss] 29/5/2024 16:03

even more food

[thanatos abysss] 29/5/2024 16:02

odey time for food

[gerbil control] 29/5/2024 15:59

Not sure how we can justify today. Anyone found any moronic excuses anywhere yet? Guild? loool

[thanatos abysss] 29/5/2024 11:01

20's soon folks

dont listen to us multi ID clown

[ming da merciless] 29/5/2024 10:44

At least it insures maker cant let it drop below 8.1p for too long, for a bit. Where is the traditional tank under the issue price though? to keep regulators happy lol

[currypasty] 29/5/2024 09:40

SkinBioTherapeutics will issue 1,875,316 ordinary shares of £0.01 per share ("Ordinary Shares") at a conversion price of 7.998651p per Ordinary Share.



nice... for some

[thanatos abysss] 29/5/2024 08:38

20's coming folks

[institutional investments] 29/5/2024 08:24

probably get an update a few days before a conversion or dilution lol

At least we know why it went up for no reason

ummmm, that reason

[institutional investments] 29/5/2024 08:23

Indeed



Institutional Investments - 24 May 2024 - 15:45:14 - 18482 of 18490 SkinBioTherapeutics PLC - Multi $bn skin health opportunities. - SBTX
game is up here. A sinker from next week. it cant hold even with a makey maker unless like off book regulator visits haha.

Well, news could stop the right next week. Not forthcoming though

Conclusion -

walk-up for bond sellers and opti, done

[theterrier] 28/5/2024 15:11

Acne, hoping we get an update which is surely due. Things I am would look out for
RNS Oct 23 + feb 24: “Two separate blends, specifically formulated by Dutch food supplement provider Winclove Probiotics BV, will be tested side-by-side in a consumer volunteer study to determine which has better efficacy. “ “150 randomly selected participants will receive product 1, the other half of the group will receive product 2. “
what happened to the two blends/products, how they differed, which one won and why, study results doc with analysis. (as we had for axis when Prof Cath as the expert presented us the study and results)
what’s novel from the current acne probiotics on market.
“Study conducted in partnership with Winclove”- what does this mean for revenues/ commercial plans / who owns blends and formulations.
what is the product launch plan, are the test blends product ready or is more work on formulations/ formats (powders/ tablets) needed. Why if so/ how long/ what’s the plan to do this/ who is doing it? Tell me the commercial roadmap
Updates tend to be “things are going” well which is poor and for once I am looking for a material update. Clear time lines and deliverables going forward that align with value creation.

[institutional investments] 28/5/2024 09:17

Somebody is angry

[institutional investments] 28/5/2024 08:55

yes it has a binary issue lol